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ABSTRACT
Type I interferons (IFNs) are produced early upon virus infection and signal through the alpha/beta interferon (IFN-/) recep-
tor (IFNAR) to induce genes that encode proteins important for limiting viral replication and directing immune responses. To
investigate the extent to which type I IFNs play a role in the local regulation of inflammation in the airways, we examined their
importance in early lung responses to infection with respiratory syncytial virus (RSV). IFNAR1-deficient (IFNAR1/) mice dis-
played increased lung viral load and weight loss during RSV infection. As expected, expression of IFN-inducible genes was mark-
edly reduced in the lungs of IFNAR1/mice. Surprisingly, we found that the levels of proinflammatory cytokines and chemo-
kines in the lungs of RSV-infected mice were also greatly reduced in the absence of IFNAR signaling. Furthermore, low levels of
proinflammatory cytokines were also detected in the lungs of IFNAR1/mice challenged with noninfectious innate immune
stimuli such as selected Toll-like receptor (TLR) agonists. Finally, recombinant IFN-was sufficient to potentiate the produc-
tion of inflammatory mediators in the lungs of wild-type mice challenged with innate immune stimuli. Thus, in addition to its
well-known role in antiviral resistance, type I IFN receptor signaling acts as a central driver of early proinflammatory responses
in the lung. Inhibiting the effects of type I IFNs may therefore be useful in dampening inflammation in lung diseases character-
ized by enhanced inflammatory cytokine production.
IMPORTANCE
The initial response to viral infection is characterized by the production of interferons (IFNs). One group of IFNs, the type I
IFNs, are produced early upon virus infection and signal through the IFN-/ receptor (IFNAR) to induce proteins important
for limiting viral replication and directing immune responses. Here we examined the importance of type I IFNs in early re-
sponses to respiratory syncytial virus (RSV). Our data suggest that type I IFN production and IFNAR receptor signaling not only
induce an antiviral state but also serve to amplify proinflammatory responses in the respiratory tract. We also confirm this con-
clusion in another model of acute inflammation induced by noninfectious stimuli. Our findings are of relevance to human dis-
ease, as RSV is a major cause of infant bronchiolitis and polymorphisms in the IFN system are known to impact disease severity.
Infections at mucosal surfaces need to be managed carefully bythe host in order to avoid damage to barrier functions. The
pathogen needs to be eradicated rapidly, but inflammation must
be tightly regulated to prevent detrimental effects on organ func-
tion. Nowhere is this more evident than in the lung, where any
excess cell infiltration or damage will markedly affect gas ex-
change. The lung is a major site of infection by viruses, and the
adverse effects of dysregulated lung inflammation have a very sig-
nificant impact on human health.
The initial response to viral infection in the lung and elsewhere
is characterized by the production of interferons (IFNs). There are
3 types of IFNs; type I IFNs (including alpha IFN [IFN-] and
IFN-), type II IFNs (IFN-), and the recently discovered type III
IFNs (IFN-). Irrespective of type, IFNs induce cell-intrinsic an-
tiviral responses, activate natural killer (NK) cells, macrophages,
and dendritic cells (DCs), and regulate innate and adaptive im-
mune responses (1–3). IFN- is mainly produced by NK and T
cells, while the synthesis of type I and type III IFNs, as well as other
cytokines such as interleukin-6 (IL-6) and tumor necrosis factor
alpha (TNF-), is induced in immune and nonimmune cell types
upon direct recognition of viral molecules by pattern recognition
receptors (PRRs) such as Toll-like receptors (TLRs) and RIG-I-
like receptors (RLRs) (1–4). The effect of IFN- is restricted to
epithelial cells at mucosal surfaces, which express the relevant re-
ceptor (1, 2). In contrast, the receptor for type I IFNs, called
IFNAR, is expressed ubiquitously by all cells. IFN-/ is produced
in the lung following infection with many viruses such as New-
castle disease virus, influenza virus, respiratory syncytial virus
(RSV), and human metapneumovirus (2, 5–9).
RSV is the major cause of infant bronchiolitis (10). While RSV
disease manifests as a simple common cold in the majority of
cases, between 2 and 3% of children develop severe bronchiolitis.
The variation in disease severity seems to be mostly due to host
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rather than viral factors and has recently been associated with
polymorphisms in several innate immunity genes, in particular
many that control the IFN system (11–14). The IFN system may
therefore be a key regulator of RSV-induced lung inflammation.
To test the impact of type I IFNs on viral infections, IFNAR1-
deficient (IFNAR1/) mice, which lack all signaling in response
to IFN-/ (15), have been widely used. For infections such as
with reovirus or Chikungunya virus, loss of IFNAR signaling is
detrimental, leading to overwhelming infection and death (16,
17). For some viruses (including influenza virus and RSV), the
effect of IFNAR1 deficiency is not as severe and does not impact
on survival from infection (18, 19).
Whether type I IFNs are involved only in inducing an antiviral
state in the lung or whether they have a more general effect in
regulation of lung inflammation has not been fully elucidated.
Here, we address this question by comparing inflammation in the
lungs ofwild-type and IFNAR1-deficientmice in response to chal-
lenge with selected TLR agonists or RSV infection. Surprisingly, in
all cases IFNAR deficiency was associated with a marked decrease
in the production of proinflammatory cytokines and chemokines
in the lung. Furthermore, type I IFN administration to the lung
potentiated inflammation in mice. We suggest that type I IFN
production and IFNAR receptor signaling not only induce an an-
tiviral state but also serve to amplify proinflammatory responses
in the respiratory tract.
MATERIALS AND METHODS
Mice, virus stocks, TLR agonists, cytokines, and infection. Six- to 10-
week-old C57BL/6 (Harlan or Charles River, United Kingdom) or
IFNAR1/ mice on a C56BL/6 background (obtained from C. Reis e
Sousa, LondonResearch Institute, London,UnitedKingdom)weremain-
tained under pathogen-free conditions under UK Home Office guide-
lines.
Plaque-purified human RSV (originally strain A2 from the ATCC,
United States) was grown inHEp-2 cells (20). Age- and sex-matchedmice
were lightly anesthetized and infected intranasally (i.n.) with 2  106
focus-forming units (FFU) of RSV in 100 l. For lung challenge with
innate stimuli, CpG (1.25 g/g bodyweight), poly(I·C) HMW (high mo-
lecular weight; 3.5 g/g), and lipopolysaccharide (LPS; 500 or 50 ng/g) in
100 l were administered i.n. (all from Invivogen). Recombinant IFN-
11 (Miltenyi Biotech) was administered i.n. at 500 ng/mouse.
Cell collection and preparation. Bronchoalveolar lavage (BAL) was
carried out by flushing 3 times with 1ml phosphate-buffered saline (PBS)
containing 0.5 mM EDTA. For determination of cellular composition in
the BAL fluid, cells were transferred onto a microscope slide (Thermo
Scientific) using a cytospin centrifuge and stained with hematoxylin and
eosin (H&E; Reagena).
Chemokine and cytokine detection.Chemokines and cytokines were
quantified by a 20-plex Luminex kit according to the manufacturer’s in-
structions (Life Technologies), and data were acquired with a Bio-plex
200 system (Bio-Rad laboratories, United Kingdom). The concentration
of cytokines in each sample was determined according to the standard
curve using the Bio-plex 6 software (Bio-Rad laboratories). IFN-2/3
(R&D), CXCL1 (R&D), or IFN- (21) levels in the BAL fluid were mea-
sured by enzyme-linked immunosorbent assay (ELISA). Data were ac-
quired on a SpectraMax Plus plate reader (Molecular Devices) and ana-
lyzed using SoftMax software (version 5.2).
Gene expression.Lungswerehomogenized inTRIzol (Invitrogen)using
a TissueLyser LT (Miltenyi Biotech). RNA extractions were performed with
chloroform-isopropanol. Removal of DNA fromTRIzol-extracted RNAwas
carried out using the DNA-free kit according to the manufacturer’s manual
(Ambion). RNA yields were determined by using aNanoDrop 1000 spectro-
photometer. cDNA conversion was performed using a high-capacity
RNA-to-cDNA kit according to the manufacturer’s instructions (Applied
Biosystems). To quantify mRNA levels in lung tissue, real-time quantitative
PCR (RT-qPCR) was performed. For mRNA analysis, the following primers
and probes were used: for Tnfa, forward primer, 5=-CATCTTCTCAAAATT
CGAGTGACAA-3=, reverseprimer,5=-TGGGAGTAGACAAGGTACAACC
C-3=, and probe, 5=-FAM-CACGTCGTAGCAAAC-TAMRA-3=; and for
Ifng, forward primer, 5=-TCAAGTGGCATAGATGTGGAAGAA-3=, reverse
primer, 5=-TGGCTCTGCAGGATTTTCATG-3=, and probe, 5=-FAM-TCA
CCATCCTTTTGCCAGTT-TAMRA-3=. Quantitative PCRs (qPCRs) for
Ifnl2/3, Ifnb, Rsad2 (Viperin), Oas1a, Eif2ak2 (PKR), and L gene were per-
formedusingprimers andprobes previously described (20, 22–24).The assay
was performedusing theQuantitect ProbePCRmastermix (Qiagen) and the
7500 Fast real-time PCR system (Applied Biosystems). For absolute quanti-
fication, the exact number of copies of the gene of interest was calculated
using a plasmidDNA standard curve for each gene. Results were normalized
using Gapdh (encoding glyceraldehyde-3-phosphate dehydrogenase) as a
housekeeping gene (Applied Biosystems). For relative quantification, the ex-
pressions of Ddx58 (RIG-I), Cxcl10, Cxcl1, Il6, Il1b, and Mx1 (all from Ap-
plied Biosystems) relative to the housekeeping geneGapdhwere determined.
The	CT (cycle threshold difference) between the target gene andGapdhwas
calculated for each sample and expressed as 2	Ct. Analyses were performed
using 7500 Fast System SDS software (Applied Biosystems).
Statistical analysis. Results are presented as means
 standard errors
of the means (SEM). The significance of results between the groups was
analyzed by two-tailed, nonparametric, unpaired Mann-Whitney t test
(Prism software; Graph-Pad Software Inc.) and is indicated in the figures
as follows: *,P 0.05; **,P 0.01; ***,P 0.001).P values of0.05were
considered significant.
RESULTS
Type I, II, and III interferon production is abrogated in
IFNAR1/ mice infected with RSV. In order to investigate the
role of IFNAR signaling in lung inflammation induced by infec-
tious challenge, wild-type (wt; C57BL/6) and IFNAR1-deficient
(IFNAR1/) mice were infected i.n. with RSV. We first assessed
the effect of IFNAR deficiency on viral control. IFNAR1/mice
showed a significantly higher viral load in the lung, asmeasured by
the copy number of viral L gene RNA, compared to wt mice from
8 h postinfection (p.i.) until day 14 p.i. (the latest time point stud-
ied; Fig. 1A). A delay in viral clearance was also apparent, as 11 of
12 IFNAR1/ mice had detectable L gene in the lungs at day 14
p.i. compared to only 1 of 12 mice in the wt group (Fig. 1A). The
increase in lung viral loadwas accompanied by greater weight loss,
a measure of infection severity (25): IFNAR1/ mice started to
loseweight at day 5, lost significantlymoreweight than infectedwt
mice, and had a slower recovery (Fig. 1B).
We then assessed the levels of IFNs in the lung early after in-
fection by mRNA analysis and protein detection. IFN- in the
BAL fluid of wt mice was detected from 8 h p.i., with peak pro-
duction at 12 to 18 h p.i. In contrast, no IFN- was detectable in
IFNAR1/ mice after RSV infection or in wt mice inoculated
with UV-inactivated RSV (Fig. 2A and data not shown). Both wt
and IFNAR1/mice displayed similar levels of IFN-mRNA at
4 h p.i., but this increased 100-fold at later time points in wt but
not IFNAR1-deficient mice (Fig. 2B). This is consistent with the
known IFNAR-dependent positive-feedback loop for type I IFN
production (26). IFN- (mRNA or protein) was not detected in
IFNAR1/ mice at any time point (Fig. 2C), in contrast to wt
mice, which showed IFN- levels peaking at 12 and 18 h p.i. for
mRNA and protein, respectively. Furthermore, although expres-
sion of IFN- mRNA was induced in IFNAR1/ mice, it was
manifestly lower than in wt controls and did not result in detect-
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able protein in BALfluid (Fig. 2D). These data confirmand extend
a previous study showing that expression of type I IFNs is reduced
in RSV-infected IFNAR1/mice (9).
We assessed whether the reduced levels of all IFNs in
IFNAR1/mice impacted the expression of selected interferon-
stimulated genes (ISGs). CXCL10 could not be detected at either
the mRNA or the protein level in lungs of IFNAR1/ mice but
was induced in wt mice (Fig. 2E). Ddx58 (RIG-I) mRNA levels
A) Weight curveB)Viral load
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
85
90
95
100
105
110
Days Post Infection
%
 o
f o
rig
in
al
 w
ei
gh
t
******
***
##
0 0.17 0.33 0.5 1 2 4 7 14
103
104
105
106
107
108
109
Days Post Infection
Lg
en
e 
co
pi
es
/ μ
g 
R
N
A ***
* **
*** ***
***
***
ND
IFNAR1-/- RSV
wt RSV
IFNAR1-/- naive
wt naive
FIG 1 Viral load and weight loss after RSV infection. C57BL/6 wt and IFNAR1/mice were infected intranasally with 2 106 FFU of RSV. RNA was isolated
from lung tissue, and after conversion into cDNA, copy numbers of RSV L gene RNAwere determined using quantitative PCR (qPCR). (A) Levels of RSV L gene
RNA in the lung tissue of wt and IFNAR1/mice at different time points after RSV infection. Copy numbers were determined using a plasmid standard. Data
shown are pooled data from 3 individual experiments with 3 to 5 mice per group in each experiment. The dotted line represents the detection limit. ND, not
detectable. (B) Weights of infected and noninfected mice were monitored daily and plotted as a percentage of weight on the day of infection (day 0). The data
shown are representative of at least 3 experiments with 3 to 5mice per group in each experiment. Error bars indicate the SEM. ***, P 0.001; **, P 0.01; *, P
0.05 comparing RSV-infected wt with RSV-infected IFNAR1/mice. ##, P 0.01 comparing RSV-infected wt with naive wt mice.
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FIG 2 Interferon responses after RSV infection of IFNAR1/ and wt mice. C57BL/6 wt and IFNAR1/mice were intranasally infected with 2 106 FFU of
RSV. (A) The level of IFN- was determined in bronchoalveolar lavage (BAL) fluid by ELISA. (B) RNA was isolated from lungs, and gene expression levels of
IFN- were determined by qPCR. (C to E) IFN- (C), IFN- (D), and interferon-stimulated gene (ISG) CXCL10 (E) gene expression levels in lung tissue and
protein production in BAL fluid were quantified. (F and G) RIG-I (Ddx58) (F) and Mx-1 (G) mRNA was determined by qPCR. Gene expression relative to
GAPDH was calculated for CXCL10, RIG-I, and Mx-1. For IFN-, IFN-, and IFN-, copy numbers were determined using a plasmid standard. The detection
limit for all assays was 200 copies and is represented by the dotted line. Data shown are representative of at least 2 experiments with 4 or 5 mice per group. Error
bars indicate the SEM. Significance when comparing RSV-infected wt with RSV-infected IFNAR1/mice: **, P 0.01; *, P 0.05.
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increased above basal expression at 4 h p.i. in both IFNAR1/
andwtmice but continued to rise only in thewtmice until 12 h p.i.
(Fig. 2F). Similar results were obtained with Mx-1 (Mx-1; Fig.
2G), Rsad2 (Viperin), Oas1a (OAS1), and Eif2ak2 (PKR) gene
expression (data not shown). In sum, our data suggest that the loss
of type I IFN receptor signaling results in decreased expression of
all IFN types early after RSV infection and prevents appropriate
induction of ISGs. This is associated with a failure to control RSV
replication and clear the virus rapidly, leading to increased pathol-
ogy (weight loss).
Proinflammatory cytokine responses are diminished in
IFNAR1/mice infected with RSV. To further evaluate the in-
flammatory response early after RSV infection, we measured ad-
ditional cytokines, including IL-6, IL-1, and TNF-. Very little,
if any, mRNA encoding these cytokines could be detected in the
lungs of RSV-infected IFNAR1/ mice (Fig. 3A). In contrast,
such mRNAs were easily detectable in wt mice as early as 4 h p.i.,
with a peak of expression at 8 h p.i. (Fig. 3A). Early infiltration of
neutrophils did not differ between wt and IFNAR1/mice (Fig.
3B), so we also analyzed the expression of CXCL1 (KC), a known
neutrophil attractant. CXCL1mRNAandproteinwere detected at
similar levels in both wt and IFNAR1/mice at early time points
(Fig. 3C). However, later during the infection CXCL1 levels were
significantly higher in wt mice (Fig. 3C).
Levels of proinflammatory cytokines and chemokines were
additionally measured in BAL fluid using a multiplex ap-
proach. IL-2, IL-4, IL-10, IL-13, and IL-17A were not detected
in the airways of either wt or IFNAR1/ mice at any time
point after infection (data not shown). For some cytokines
(IL-6, IL-1, TNF-, and IL-12p40), there were measurable
levels in IFNAR1/ mice at 4 to 8 h p.i., but this was not
comparable to the levels in wt mice, which were 5 to 10 times
greater (Fig. 4). For other cytokines and chemokines such as
IL-1, granulocyte-macrophage colony-stimulating factor
(GM-CSF), IL-5, IL-12p40, CXCL9, and CCL3, there was no or
very little induction in the airways of IFNAR1/ mice at any
time point, while wt mice showed substantial levels peaking at
8 to 12 h p.i. (Fig. 4B). Overall, these results indicate that the
lack of type I IFN receptor signaling results in a marked reduc-
tion in induction of proinflammatory mediators in lung and
airways upon pulmonary viral infection.
IFNAR1-deficient mice display reduced proinflammatory
cytokine responses to lung challenge with TLR agonists. To in-
vestigate whether similar results applied to noninfectious stim-
ulation of the airways, we administered different innate im-
mune stimuli intranasally (i.n.) to wt and IFNAR1/ mice.
Mice were sacrificed 24 h following administration of CpG,
poly(I·C), or LPS, and lung cytokine expression was measured
using qPCR and ELISA. We observed significantly reduced
mRNA levels of IFN- in response to the TLR9 agonist CpG
and the TLR4 agonist LPS and of CXCL10 in response to all
TLR agonists tested in IFNAR1/mice (Fig. 5A). The expres-
sion of proinflammatory cytokines was also quantified. De-
creased induction of IL-6, IL-1, and TNF- mRNA was ob-
served with the TLR3, RIG-I, andMDA-5 agonist, poly(I·C), in
IFNAR1/ mice. Moreover, a significant reduction in IL-6
mRNA was seen in IFNAR1/ mice treated with CpG com-
pared to wt mice (Fig. 5A). Similarly, LPS-dependent induc-
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FIG 3 Diminished induction of proinflammatory cytokine mRNA in IFNAR1/ mice during RSV infection. C57BL/6 wt and IFNAR1/ mice were intra-
nasally infected with 2 106 FFU of RSV. (A) RNA was isolated from lungs, and gene expression levels of IL-6, IL-1-, and TNF- were determined by qPCR.
(B) Percentage of neutrophils in the BAL fluid at indicated days postinfection. Data shown are pooled data from 3 individual experiments with 3 to 5 mice per
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tion of IL-1mRNA was reduced in lungs of IFNAR1/mice
(Fig. 5A). A similar pattern was detected at the protein level:
IFN- was not induced after poly(I·C) treatment, and IL-6 was
not induced by any of the TLR agonists in IFNAR1/ mice
(Fig. 5B). Thus, the lack of type I IFN receptor decreases the
lung inflammatory response provoked by innate stimulation of
the airways.
IFN-potentiates proinflammatory cytokine induction.The
above results suggested that type I IFNs might potentiate proin-
flammatory responses in the lung. To explicitly test this hypothe-
sis, one representative type I IFN, IFN-11, was administered in-
tranasally to mice concomitantly with innate immune challenge.
The dose of IFN-was similar to a dose previously used to inhibit
RSV infection (8), and LPS was chosen as the stimulus because it
does not induce high expression of type I IFNs in the lung (data
not shown).Mice that received both IFN- and a suboptimal dose
of LPS showed increased lung expression of mRNAs encoding
IL-6 and TNF- (Fig. 6A) or IFN- (data not shown) 24 h post-
challenge compared to mice that received only LPS or IFN-.
Interestingly, intranasal administration of IFN- alone was
sufficient to induce an increase in IL-6, TNF-, IFN-, and
IL-1 mRNA at 12 h (Fig. 6B) and IL-6 and TNF- mRNA in
the lung at 24 h (Fig. 6A). This was not observed in IFNAR1/
mice, indicating that the effect is dependent on signaling via
IFNAR (Fig. 6) and not due, for example, to a contaminant. We
conclude that type I IFNs markedly potentiate acute proin-
flammatory responses induced by innate immune stimulation
of the airways.
DISCUSSION
Type I IFNs are produced early after viral infection as a first line of
host defense. They act on all cell types via the ubiquitously ex-
pressed IFNAR to induce increased expression of more than 300
different genes whose products eventually interfere with viral rep-
lication and viral spread, aswell as lead to the initiation of immune
responses (3, 10). Previous studies addressing the role of type I
IFNs in the lung have focusedmainly on adaptive immunity (8, 9,
19, 27, 28). Thus, the importance of type I IFNs signaling for the
early innate immune response in the lung remains elusive. In this
study, we uncover a general role for IFNAR signaling in amplify-
ing acute lung inflammatory responses to innate stimuli. Further,
we provide in vivo evidence for an important role of IFNAR in
innate resistance to RSV lung infection and show that signaling
through IFNAR is necessary for coordinating the inflammatory
response to the virus. Our data suggest that type I IFNs are pivotal
contributors to lung inflammation.
We anticipated that other IFNs might compensate for the lack
of type I IFN signaling during RSV infection, as previously shown
for influenza virus (9, 29–31), but were surprised to find that our
data did not support this hypothesis; neither IFN-nor IFN-was
upregulated in the lungs of IFNAR1/ mice during the early
stages of RSV infection. Instead, expression of all IFNs and ISGs
was decreased in RSV-infected IFNAR1/mice compared to wt
controls. This suggests that type I IFNs are involved in controlling
the expression of IFN-/, IFN-, IFN-, and ISGs during RSV
infection. For IFN-/, this is expected because type I IFN pro-
A)
GM-CSF IL-5IL-1-α
0 4 8 12 18 24 48
0
50
100
150
200
Time Post Infection (hrs)
IL
-1
2p
40
 (p
g/
m
l)
**
** *
**
0 4 8 12 18 24 48
0
500
1000
1500
2000
Time Post Infection (hrs)
C
XC
L9
 (p
g/
m
l)
****
**
*
0 4 8 12 18 24 48
0
50
100
150
200
Time Post Infection (hrs)
C
C
L3
 (p
g/
m
l) 
****
**
** *
0 4 8 12 18 24 48
0
50
100
150
200
Time Post Infection (hrs)
IL
-1
α
 (p
g/
m
l) **
0 4 8 12 18 24 48
0
50
100
150
200
Time Post Infection (hrs)
G
M
-C
SF
 (p
g/
m
l) ***
*
**
0 4 8 12 18 24 48
0
200
400
600
800
Time Post Infection (hrs)
IL
-5
 (p
g/
m
l)
**
**
**
**
0 4 8 12 18 24 48
0
1000
2000
3000
4000
Time Post Infection (hrs)
IL
-6
 (p
g/
m
l)
**
** **
*
B)
IL-6 TNF-α
IL-12p40 CXCL9 CCL3
0 4 8 12 18 24 48
0
20
40
60
80
100
Time Post Infection (hrs)
IL
-1
β 
(p
g/
m
l)
**
**
0 4 8 12 18 24 48
0
1000
2000
3000
4000
Time Post Infection (hrs)
TN
F-
α
 (p
g/
m
l)
****
**
**
IL-1β
FIG4 Reduced levels of proinflammatory cytokines in IFNAR1/mice duringRSV infection. C57BL/6wt and IFNAR1/micewere intranasally infectedwith
2 106 FFU of RSV. At different time points postinfection protein levels of IL-6, IL-1, TNF-, IL-1, GM-CSF, IL-5, IL-12p40, CXCL9, and CCL3 production
were determined in BAL fluid by Luminex. Data shown are representative of at least 2 experiments with 4 or 5 mice per group. Error bars indicate the SEM.
Significance when comparing RSV-infected wt with RSV-infected IFNAR1/mice: **, P 0.01; *, P 0.05.
Goritzka et al.
6132 jvi.asm.org Journal of Virology
duction relies on a positive-feedback loop through the type I IFN
receptor (26). In addition, previous studies have shown that type I
IFNs play a critical role in induction of IFN- gene expression
through the activation of STAT4 (32, 33) or increased signaling
through other cytokine receptors such as IFN- receptor by in-
creased levels of STAT1 (19, 34). Furthermore, since the IFN re-
sponses were reduced in IFNAR1/ mice, this resulted in a di-
minished induction of ISGs as has previously been shown for TLR
stimulation (35, 36) and for bonemarrow-derived DCs (BMDCs)
stimulated with RSV (37). Therefore, type I IFN production with
subsequent IFNAR signaling is a key component of the entire IFN
response early after RSV infection.
Surprisingly, our data indicate that type I IFN production and
subsequent IFNAR signaling are also a key component of the en-
tire inflammatory response. Indeed, we found that the induction
of proinflammatory cytokines (e.g., IL-6, IL-1, and TNF-) was
abrogated in the lungs of IFNAR1/mice after RSV infection. A
similar pattern was seen in BAL fluid for a broader array of pro-
inflammatory cytokines and chemokines. Furthermore, IFNAR
deficiency decreased the induction of proinflammatory cytokines
in response to airway challenge with different innate immune
stimuli, and IFN- augmented the proinflammatory response to
LPS stimulation. Also, IFN- alone given intranasally drove a
rapid and transient induction of proinflammatory cytokines in
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the lung. It has been shown that bone marrow-derived macro-
phages can produce CCL2 after stimulation with IFN- (38) and
that recombinant IFN- (rIFN-) potentiates serum TNF- re-
sponse to LPS administration (39). Furthermore, the dependence
on IFNAR signaling for cytokine production has previously been
suggested in studies where BMDCs from IFNAR1/ mice were
found to produce less IL-12p70 after RSV exposure (37) or after
treatment with select combinations of TLR agonists (36). How-
ever, it is possible that the effect of IFN- in the lung is not to
initiate de novo cytokine synthesis but to amplify that which has
been initiated by other stimuli such as environmental endotoxins
or airway commensals. Whichever the case, our data point to a
hitherto unappreciated key role for IFNAR signaling in amplifying
lung inflammation. This has been noted in systemic models of
inflammation, where IFNAR1/ mice have been shown to be
more resistant to LPS-induced septic shock and to lethal immu-
nopathology induced by systemic Candida albicans infection (3,
40, 41).
There are several possible mechanisms that could explain our
findings. First, proinflammatory cytokines are regulated mainly
by the transcription factor NF-B. Synergy between IFNAR sig-
naling and NF-B pathways has been suggested (36), and a recent
report revealed multiple IFN-stimulated pathways that can acti-
vate NF-B (42). However, NF-B is activated at 0.5 to 1.5 h after
RSV inoculation independently of viral replication (43). This
could explain the early induction of some cytokines such as
IFN-, TNF-, and CXCL1, which were detected at 4 h p.i. in
IFNAR1/ mice. Another possibility is that the expression of
molecules involved in virus recognition (e.g., RIG-I), signaling
(e.g., MyD88), and cytokine production (e.g., MTOR) (44) is de-
pendent on type I IFN receptor signaling. A third possibility is that
the cellular source of the proinflammatory cytokines needs to be
recruited into the lung and that this recruitment is dependent on
IFNAR signaling. That source is unlikely to be neutrophils, as we
observed comparable induction of CXCL1 and early infiltration of
neutrophils into the airways of RSV-infected IFNAR1/ and wt
mice.
Proinflammatory cytokines are known to cause discomfort
and reduce appetite, leading to weight loss (10, 45). Oddly,
we observed increased weight loss during RSV infection in
IFNAR1/ mice, even though proinflammatory cytokines
were not detected. The weight loss during RSV infection coin-
cides with the infiltration of T cells (days 5 to 7 p.i.) and is
reduced if T cells are depleted (46). However, during both RSV
and Sendai virus infections, virus-specific T cells in IF-
NAR1/ mice are generated in numbers comparable to those
seen in wt mice (references 19 and 47 and data not shown).
Therefore, we suppose that the increased weight loss in the
IFNAR1/ mice is not a manifestation of the immune re-
sponse but, rather, a direct consequence of increased viral load
and possible associated cytopathic damage to the lung struc-
ture and epithelial barrier.
The notion that weight loss can be a direct manifestation of
RSV load has been previously suggested (25). Consistent with that
notion, we found that IFNAR1/mice were more permissive to
RSV infection both asmeasured byweight loss and asmeasured by
quantitating viral RNA in the lungs. This is in contrast to results
from other groups who have found no effect of IFNAR in the
resistance to RSV (19, 31) and might be explained by the use of
distinct mouse strains (19), volumes and virus titers used for in-
fections, virus purity (31), and/or methods for viral detection
(qPCRversus plaque assay). In addition, differences inmicrobiota
amongmice from different animal facilities might be a contribut-
ing factor, as increasingly appreciated (48).
In summary, our study shows that lack of signaling through the
IFNAR has a negative impact on the production of proinflamma-
tory cytokines in the lung both after exposure to different innate
stimuli and during RSV infection. This reveals a dual role for type
I IFNs during respiratory infections, limiting viral replication
while at the same time regulating the cytokine milieu. Further-
more, it suggests that an excessive induction of type I IFNs could
potentially be detrimental for the host by driving excessive lung
inflammation. The demonstration that type I IFNs can amplify
lung inflammation when given exogenously may have applica-
tions in the design of vaccines or therapeutics for use at mucosal
FIG 6 Recombinant IFN- can amplify proinflammatory cytokine induction.
(A) C57BL/6 wt mice were intranasally challenged with a suboptimal dose of
LPS (50 ng/g body weight) with or without recombinant IFN-11 (rIFN-11)
(500 ng/mouse), and lungs were collected after 24 h. (B) C57BL/6 wt and
IFNAR1/ mice were intranasally challenged with rIFN- (500 ng/mouse),
and lungs were collected after 12 h. RNA was isolated from lungs, and gene
expression levels of IL-6 and TNF- (A) and IL-6, TNF-, IFN-, and IL-1
(B) were determined by qPCR. Gene expression relative to GAPDH was cal-
culated for IL-6 and IL-1, and for TNF- and IFN- copy numbers were
determined using a plasmid standard. Data shown are pooled data from 2
individual experiments with 4 or 5 mice per group in each experiment. Error
bars indicate the SEM. Significance when comparing RSV-infected wt with
RSV-infected IFNAR1/mice: ***, P 0.001; **, P 0.01; *, P 0.05.
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surfaces; conversely, local IFN blockade might be deployed as a
strategy by which to limit lung inflammation.
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